Meeting
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
Authors
Rahima Jamal
Centre Hospitalier de l'Université de Montréal - Hopital Notre-Dame, Montreal, QC, Canada
Rahima Jamal , Karl Belanger , Jennifer Elisabeth Friedmann , Jean-Pierre M. Ayoub , Eftihia Cocolakis , Shirin Kazemi , Jeanne Dionne , Caroline Lambert , HB Le , Leon Van Kempen , Alan Spatz , Rejean Lapointe , Wilson H. Miller Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01676649
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9066)
DOI
10.1200/jco.2014.32.15_suppl.9066
Abstract #
9066
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
First Author: Asim Amin
Poster
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
First Author: Howard Kaufman
Poster
2014 ASCO Annual Meeting
Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
First Author: Sigrun Hallmeyer